Evaluation of predictive variables in locally advanced pancreatic adenocarcinoma patients receiving definitive chemoradiation

Practical Radiation Oncology

Volumn 2, Issue 2, 2012, Pages 77-85

  Rudra, Sonali ^a   Narang, Amol K ^b   Pawlik, Timothy M ^b   Wang, Hao ^b   Jaffee, Elizabeth M ^b   Zheng, Lei ^b   Le, Dung T ^b   Cosgrove, David ^b   Hruban, Ralph H ^b   Fishman, Elliot K ^b   Tuli, Richard ^b   Laheru, Daniel A ^b   Wolfgang, Christopher L ^b   Diaz, Luis A ^b   Herman, Joseph M ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CONTRAST MEDIUM; FLUOROURACIL; GEMCITABINE; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BILE DUCT OBSTRUCTION; CANCER GROWTH; CANCER INCIDENCE; CHEMORADIOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; DEHYDRATION; DIARRHEA; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISTANT METASTASIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME VARIABLE; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RADIATION DOSE; SEPSIS; SURVIVAL TIME; THERAPY DELAY; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84858862692     PISSN: 18798500     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.prro.2011.06.009     Document Type: Article

References (36)

1. Klaassen D.J., MacIntyre J.M., Catton G.E., et al. Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil-an Eastern Cooperative Oncology Group study. J Clin Oncol 1985, 3:373-378.
2. Crane C.H., Janjan N.A., Evans D.B., et al. Toxicity and efficacy of concurrent gemcitabine and radiotherapy for locally advanced pancreatic cancer. Int J Pancreatol 2001, 29:9-18.
3. Callery M.P., Chang K.J., Fishman E.K., et al. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol 2009, 16:1727-1733.
4. Leibel S.A., Scott C.B., Mohiuddin M., et al. The effect of local-regional control on distant metastatic dissemination in carcinoma of the head and neck: results of the analysis from the RTOG head and neck database. Int J Radiat Oncol Biol Phys 1991, 21:549-556.
5. Murphy J.D., Adusumilli S., Griffith K.A., et al. Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 2007, 68:801-808.
6. Moertel C.G., Frytak S., Hahn R.G., et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: the Gastrointestinal Tumor Study Group. Cancer 1981, 48:1705-1710.
7. Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst 1988, 80:751-755. The Gastrointestinal Tumor Study Group.
8. Burris H.A., Moore M.J., Andersen J., et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997, 15:2403-2413.
9. Lawrence T.S., Eisbruch A., Shewach D.S. Gemcitabine-mediated radiosensitization. Semin Oncol 1997, 24(S7):24-28.
10. Loehrer P.J., Powell M.E., Cardenes H.R., et al. A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: E4201. J Clin Oncol 2008, 26(suppl):4506. [Abstract].
11. Chauffert B., Mornex F., Bonnetain F., et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol 2008, 19:1592-1599.
12. Ikeda M., Okada S., Tokuuye K., et al. Prognostic factors in patients with locally advanced pancreatic carcinoma receiving chemoradiotherapy. Cancer 2001, 91:490-495.
13. Huang P.I., Chao Y., Li C.P., et al. Efficacy and factors affecting outcome of gemcitabine concurrent chemoradiotherapy in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2009, 73:159-165.
14. Clement M., Bandukwala S., Burman D., et al. Interconversion of three measures of performance status: an empirical analysis. Eur J Cancer 2010, 46:3175-3183.
15. Ishii H., Okada S., Nose H., et al. Prognostic factor in patients with advanced pancreatic cancer treated with systemic chemotherapy. Pancreas 1996, 12:267-271.
16. Lundin J., Roberts P.J., Kuusela P., et al. The prognostic value of preoperative serum levels of CA 19-9 and CEA in patients with pancreatic cancer. Br J Cancer 1994, 69:515-519.
17. Laws E.R., Parney I.F., Huang W., et al. Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. J Neurosurg 2003, 99:467-473.
18. Jeremic B., Milicic B., Dagovic A., et al. Pretreatment clinical prognostic factors in patients with stage IV non-small cell lung cancer (NSCLC) treated with chemotherapy. J Cancer Res Clin Oncol 2003, 129:114-122.
19. Krishnan S., Rana V., Janjan N.A., et al. Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy. Cancer 2007, 110:47-55.
20. Huguet F., Andre T., Hammel P., et al. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol 2007, 25:326-331.
21. Iacobuzio-Donahue C.A., Fu B., Yachida S., et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol 2009, 27:1806-1813.
22. Whittington R., Solin L., Mohiuddin M., et al. Multimodality therapy of unresectable pancreatic adenocarcinoma. Cancer 1984, 54:1991-1998.
23. Ben-Josef E., Shields A.F., Vaishampayan U., et al. Intensity modulated radiation therapy (IMRT) and concurrent capecitabine for pancreatic cancer. Int J Radiat Oncol Biol Phys 2004, 59:454-459.
24. Yovino S., Poppe M., Jabbour S., et al. Intensity-modulated radiation therapy significantly improves acute gastrointestinal toxicity in pancreatic and ampullary cancers. Int J Radiat Oncol Biol Phys 2011, 79:158-162.
25. Willett C., DelCastillo F., Goldberg S., et al. Long-term results of intraoperative electron beam radiation therapy for unresectable pancreatic cancer. Ann Surg 2005, 241:295-299.
26. Koong A.C., Christofferson E., Le Q.T., et al. Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2005, 63:320-323.
27. Schellenberg D., Goodman K.A., Lee F., et al. Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2008, 72:678-686.
28. Stanford University Phase II multi-institutional study to evaluate the efficacy of gemcitabine and fractionated stereotactic radiotherapy for unresectable pancreatic adenocarcinoma. clinicaltrials.gov [Internet] 2000, National Library of Medicine (US), Bethesda (MD), [cited 2011 Jan 18]. Available at, [NLM identifier: NCT01146054]. Accessed June 21, 2011. http://clinicaltrials.gov/ct2/show/NCT01146054.
29. Munter M., Timke C., Abdollahi A., et al. Final results of phase II trial [PARC-Study ISRCTN56652283] for patients with primary inoperable locally advanced pancreatic cancer combining intensity modulated radiotherapy (IMRT) with cetuximab and gemcitabine. J Clin Oncol 2008, 26:S4613.
30. Ma W.W., Herman J.M., Jimeno A., et al. A tolerability and pharmacokinetic study of adjuvant erlotinib and capecitabine with concurrent radiation in resected pancreatic cancer. Transl Oncol 2010, 3:373-379.
31. Goldstein S.D., Ford E.C., Duhon M., et al. Use of respiratory-correlated four dimensional computed tomography to determine acceptable treatment margins for locally advanced pancreatic adenocarcinoma. Int J Radiat Oncol Biol Phys 2010, 76:597-602.
32. Parg W.G., Yan B.M., Schellenberg D., et al. EUS-guided gold fiducial insertion for image-guided radiation therapy of pancreatic cancer: 50 successful cases with fluoroscopy. Gastrointest Endosc 2010, 71:513-518.
33. Ford E.C., Herman J., Yorke E., et al. 18F-FDG PET/CT for image-guided and intensity-modulated radiotherapy. J Nucl Med 2009, 50:1655-1665.
34. Fogelman D.R., Schreibman S., Sherman W., et al. Neoadjuvant GTX and radiation for unresectable pancreatic cancer: A prospective phase II Trial. Proc GI Am Soc Clin Oncol 2007, (Abstract 143).
35. Rose D.M., Delbeke D., Beauchamp R.D., et al. 18-Fluorodeoxyglucose positron emission tomography (18-FDG PET) in the management of patients with pancreatic cancer. Ann Surg 1998, 229:1784-1792.
36. Evans D.B., Varadhachary G.R., Crane C.H., et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008, 26:3496-3502.